Researchers will analyze nearly 200 patients at 30 sites throughout the United States.
Here are five takeaways:
1. The study is a prospective, randomized, active treatment-controlled evaluator-binded multicenter study.
2. The study aims to establish that hyaluronan-based scaffold with autologous bone marrow aspirate concentrate is the best treatment for articular knee cartilage defect lesions.
3. Anika Therapeutics’ HYALOFAST is a biodegradable scaffold that facilitates cartilage regeneration in patients with cartilage defects.
4. In Europe, patients treated with HYALOFAST successfully regenerated hyaline-like cartilage.
5. Anika Therapeutics specializes in therapeutics based on its proprietary hyaluronic acid technology.
More articles on orthopedics:
Orthopedic surgeon to know: Dr. Matthew Beal of Northwestern Medicine
Orthofix shares witness high volume increase: 5 facts
Distracted walking causes more injuries and hospital visits — 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
